Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Merck & Co. is expanding its immunotherapy portfolio with the purchase of Tilos Therapeutics. The deal, worth up to $773 million, gives Merck a stable of cancer therapies aimed at modulating the activity of TGFβ, a cytokine that helps dampen the immune system response. Cambridge, Massachusetts–based Tilos has developed antibodies that act on latentcy-associated peptide, a protein that envelops TGFβ. The strategy both prevents the release of TGFβ and targets certain key cells for deletion from the tumor microenvironment.
This article has been sent to the following recipient: